Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2008 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
Information provided by:
Shahid Beheshti University of Medical Sciences Identifier:
First received: January 8, 2007
Last updated: January 28, 2008
Last verified: January 2008
a comparison of efficacy and adverse side effects occurrence of Doxycycline and Azithromycin in the management of moderate acne vulgaris

Condition Intervention Phase
Drug: Doxycycline
Drug: Azithromycin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti University of Medical Sciences:

Primary Outcome Measures:
  • change in acne lesions [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • global response rates, patient's own assessment, side effects and compliance [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: August 2006
Estimated Study Completion Date: February 2008
Estimated Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Azithromycin
Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
Other Name: kimidarou
Active Comparator: 2 Drug: Doxycycline
Cap 100mg- 100mg/daily
Other Name: Razak lab


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Between 18 to 30 year old
  • Moderate facial Acne(At least 10 inflammatory lesions with maximum 3 nodules and pseudocysts

Exclusion Criteria:

  • Pregnancy
  • Breast Feeding
  • Acne Fulminant
  • Acne conglobate
  • Isotretinoin therapy within past 6 months
  • topical treatment in last 2 weeks
  • use of systemic antibiotic in the last month
  • Hyperandrogenism symptoms
  • Menstrual irregularity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00419848

Iran, Islamic Republic of
Shaheed Beheshti Medical University, Skin research center
Tehran, Iran, Islamic Republic of, 198994148
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Study Chair: Parviz Toossi, M.D. Skin Research Center
Principal Investigator: Hamideh Moravvej, M.D. Skin Research Center
Principal Investigator: Akbar Mousazadeh halim, M.D. Skin Research Center
  More Information

Responsible Party: Skin research center, Shaheed Beheshti Medical unversity Identifier: NCT00419848     History of Changes
Other Study ID Numbers: src-hmj-1385 
Study First Received: January 8, 2007
Last Updated: January 28, 2008
Health Authority: Iran: Ministry of Health

Keywords provided by Shahid Beheshti University of Medical Sciences:

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on January 18, 2017